News
Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum
Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups
Clovis Oncology, Inc. (NASDAQ: CLVS), today announced results from a subgroup analysis of data from the monotherapy comparison of the randomized, Phase 3 ATHENA (GOG-3020/ENGOT-ov45) trial
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of updated findings from the Phase II SUMMIT basket trial of neratinib for HER2 (ERBB2)-mutant
DGAP-Adhoc: Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate
Vistagen to Participate in Upcoming Morgan Stanley and Baird Healthcare Conferences
Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety
Xencor Appoints Nancy Valente, M.D., to Board of Directors
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the
FDA and EMA Accept Regulatory Submission for Pfizer’s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted for filing the New Drug Application (NDA) for ritlecitinib for adults and adolescents 12 years of
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences in New York, including:
-
Baird 2022 Global Healthcare
Nanobiotix: Voting Rights and Shares Capital of the Company
Regulatory News:
Nanobiotix (Paris:NANO) (NASDAQ:NBTX):
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website
Fortune Ranks Agilent Among Top Workplaces in Health Care
Agilent Technologies Inc. (NYSE: A) today announced that the company has been named a “Best Workplace in Health Care” in the United States by Fortune magazine. Agilent’s number 17 ranking is based
Vistagen to Proceed with PALISADE-2 Phase 3 Clinical Trial of PH94B in Social Anxiety Disorder following Interim Analysis
Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety
Silence Therapeutics to Participate in September Investment Conferences
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Silence Therapeutics Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the
Sensorion to participate in the Inner Ear Biology Workshop in September 2022
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer
Regulatory News:
NANOBIOTIX (Euronext: NANO – Nasdaq: NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with
Agilent Receives Award for Sustainability Leadership
Agilent Technologies Inc. (NYSE: A) has received an award for leadership in advancing environmental sustainability from the Business Intelligence Group. The award recognizes Agilent’s
Positive Readouts for Transgene’s Clinical Stage Candidates Generated by its Two Innovative Platforms, with Further Clinical Data Expected in the Second Half of 2022
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial results for
Simulations Plus to Present at Baird 2022 Global Healthcare Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
FDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women
Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designation from the U.S. Food and
Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Premier, Inc.’s Subsidiary Contigo Health, LLC, to Acquire Contracts With 900,000 Providers and Licenses to Cost Containment Technology
Premier, Inc. (NASDAQ: PINC) subsidiary Contigo Health, LLC, a provider of comprehensive services that optimize employee health benefits, today announced an agreement to acquire key assets from
Savara Presented Data at the European Respiratory Society (ERS) International Congress 2022
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented three posters at the ERS International Congress 2022 that took place September